Related Experiment Video
Updated: Jun 24, 2026

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
Published on: September 29, 2016
Signalosomes as Therapeutic Targets
Alejandra Negro1, Kimberly Dodge-Kafka, Michael S Kapiloff
1Cardiac Signal Transduction and Cellular Biology Laboratory, Department of Medicine and Pediatrics, University of Miami Miller School of Medicine, R198, P.O. Box 016960, Miami, FL 33101.
Insights
Cardiac hypertrophy, a heart response to stress, can lead to heart failure. Targeting intracellular signalosomes offers a more selective approach to treating pathological cardiac hypertrophy and preventing heart failure.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Cell Signaling
Background:
- Cardiac hypertrophy is the heart's primary response to biomechanical stress but can lead to heart failure.
- Current therapies targeting cell surface molecules have significant off-target effects.
- Understanding intracellular signaling is key to developing targeted therapies.
Purpose of the Study:
- To explore the role of intracellular signalosomes in cardiac hypertrophy.
- To identify potential therapeutic targets within the cardiac myocyte.
Main Methods:
- Utilized cultured cardiac myocytes, transgenic/knock-out animal models, and pharmacological studies.
- Investigated the formation and function of signalosomes, including those involving mAKAPβ and AKAP-lbc scaffold proteins.
Main Results:
- Identified key molecules and highlighted redundancy in hypertrophic signaling pathways.
- Demonstrated that signalosomes enhance specificity and efficiency of hypertrophic signal transduction.
- Showcased signalosomes' role in altering gene expression, cell size, and chamber remodeling.
Conclusions:
- Intracellular signalosomes are crucial for specific and efficient hypertrophic signaling.
- Targeting these signalosomes may offer a more selective therapeutic strategy for cardiac hypertrophy.
- Further understanding of molecular mechanisms regulating signalosomes could lead to new treatments for heart failure.
Abstract:
Cardiac hypertrophy is the predominant compensatory response of the heart to a wide variety of biomechanical stressors, including exercise, hypertension, myocardial infarction, intrinsic cardiomyopathy or congenital heart disease. Although cardiac hypertrophy can maintain cardiac output in response to elevated wall stress, sustained cardiac hypertrophy is often accompanied by maladaptive remodeling which can ultimately lead to heart failure. Cultured cardiac myocytes, transgenic and knock-out animal models, and pharmacological studies have not only revealed key molecules involved in hypertrophic signaling, but have also highlighted the redundancy in the hypertrophic signaling cascade. Currently, the majority of existing therapies for inhibition of pathologic cardiac hypertrophy and heart failure target molecules on the surface of cardiac myocytes, such as G-protein coupled receptors (GPCRs) and ion channels. Because these molecules are upstream of multiple intracellular signaling pathways, however, current therapy is often accompanied by significant off-target effects and toxicity. More recently, research has focused on identifying the intracellular effectors of these signaling cascades in the hope that more selective drugs may be rationally designed for therapeutic intervention.Within the cardiac myocyte, the formation of discrete multimolecular complexes, or 'signalosomes', is an important mechanism for increasing the specificity and efficiency of hypertrophic signal transduction. In response to extracellular stimuli, these signalosomes can alter gene and protein expression, cell size, and chamber remodeling, such as in the case of the signalosomes formed by the mAKAPβ and AKAP-lbc scaffold proteins. A better understanding of the basic molecular mechanisms regulating the compartmentation and scaffolding of signaling molecules could lead to the development of new clinical tools that may prevent the development of heart failure and minimize negative impacts on physiological processes.
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Amplifying Signals via Enzymatic Cascade
Signal Transduction: Overview
Typically, signal transduction involves three...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Amplifying Signals via Second Messengers
Pharmacogenomics: Identification of New Drug Targets

